Global healthcare AI company Huma Therapeutics has raised over US$80m to speed the launch of its digital health platform.
The Series D funding round, alongside investments from leading industry partners since its Series C round, created a total issuance of shares by Huma of over $80m. With this round, Huma has now raised over $300m.
It involves the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer and others.
Huma has also announced the launch of its Huma Cloud Platform – a technology ecosystem designed to support the company’s own digital health initiatives, and “empower others to launch and scale their projects efficiently”.
Huma aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days.
The Huma Cloud Platform enables no-code configuration of regulated disease management tools for any therapeutic area, as well as a library of pre-built modules and device connectivity capabilities.
It will also provide a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms and a marketplace.
The Huma Cloud Platform is built to serve the company’s existing regulated products. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EU MDR Class IIb and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models.
The regulatory status of the Huma Cloud Platform significantly reduces the cost, time, and risks associated with bringing digital health projects to life.
Huma is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions.
To date, Huma’s technology has powered projects in over 3,000 hospitals and clinics.
The platform has been used to engage and screen over 35 million individuals, with 1.8 million active users across its products in over 70 countries.
Huma also collaborates with over half of the top 20 pharmaceutical companies globally and has been involved in major national healthcare projects worldwide.
The firm has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work; for example a feature called “10x Nurse” that reduces administrative tasks and brings automation to the patient review process with a human in the loop.
This opens new possibilities, such as efficiently managing chronic diseases with fewer staff or using real-time monitoring systems to ensure patients are on the correct treatment pathways while keeping humans still in the loop.
Dan Vahdat, founder and CEO of Huma, said, “We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce.
“We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive.”
